Sachin Gupta (Ruchi Gupta)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Idiopathic Pulmonary Fibrosis

Systemic Lupus Erythematosus

Placebo Controlled

Top Venues

Pulmonary therapy

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Tejaswini Kulkarni, Chad A Newton, Sachin Gupta, Katerina Samara, Elana J Bernstein
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary therapy 10 (3) (2024)
Tejaswini Kulkarni, Chad A Newton, Sachin Gupta, Katerina Samara, Elana J Bernstein
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary therapy 10 (3) (2024)
Tejaswini Kulkarni, Chad A Newton, Sachin Gupta, Katerina Samara, Elana J Bernstein
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary therapy 10 (3) (2024)
Sayantani B Sindher, Christopher M Warren, Christina E Ciaccio, Arpamas Seetasith, Yutong Liu, Sachin Gupta, Ruchi Gupta
Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis. Journal of medical economics 27 (1) (2024)
Sayantani B Sindher, Christopher M Warren, Christina E Ciaccio, Arpamas Seetasith, Yutong Liu, Sachin Gupta, Sachin Gupta
Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis. Journal of medical economics (2024)
Tejaswini Kulkarni, Chad A Newton, Sachin Gupta, Katerina Samara, Elana J Bernstein
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary therapy 10 (3) (2024)
Tejaswini Kulkarni, Chad A Newton, Sachin Gupta, Katerina Samara, Elana J Bernstein
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary therapy (2024)